Area of research
Oncology · Cancer Research
Research interest
Research interests include Breast Cancer Treatment Studies, HER2/EGFR in Cancer Research, Cancer Immunotherapy and Biomarkers, and Advanced Breast Cancer Therapies.
Association between risk-reducing surgeries and survival in young BRCA carriers with breast cancer: an international cohort study
Clinical Behavior of Breast Cancer in Young <i>BRCA</i> Carriers and Prediagnostic Awareness of Germline <i>BRCA</i> Status
Current controversies in the use of Oncotype DX in early breast cancer
A-BRAVE trial: a phase III randomized trial with anti-PD-L1 avelumab in high-risk triple-negative early breast cancer patients
Effectiveness comparison of palbociclib, ribociclib and abemaciclib in patients with HR+/HER2- aBC: Updated results from the real-world, Italian study PALMARES-2.
The use of bone-modifying agents in early breast cancer: AIOM Guidelines update and perspectives
Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer
Immune and gene-expression profiling in estrogen receptor low and negative early breast cancer
A-BRAVE trial: A phase III randomized trial with avelumab in early triple-negative breast cancer with residual disease after neoadjuvant chemotherapy or at high risk after primary surgery and adjuvant chemotherapy.
Impact of hormone receptor status and tumor subtypes of breast cancer in young BRCA carriers
Clinical applications of radiomics and deep learning in breast and lung cancer: A narrative literature review on current evidence and future perspectives
Characterization of HER2‐low breast cancer in young women with germline <i>BRCA1/2</i> pathogenetic variants: Results of a large international retrospective cohort study
Characteristics and clinical outcomes of breast cancer in young BRCA carriers according to tumor histology
Association of tumor-infiltrating lymphocytes (TILs) and immune signatures with PAM50 intrinsic subtyping hormone receptor-positive (HR+)/HER2-negative (HER2-) early breast cancer (BC): A translational analysis of two multicentric neoadjuvant trials.
Pregnancy After Breast Cancer in Young <i>BRCA </i>Carriers
Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer
Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors
Nine-Week Versus One-Year Trastuzumab for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: 10-Year Update of the ShortHER Phase III Randomized Trial
Characterization of Gut Microbiome Composition in Patients with Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy
Metastatic site patterns by intrinsic subtype and HER2DX in early HER2-positive breast cancer
Association of tumor-infiltrating lymphocytes with recurrence score in hormone receptor-positive/HER2-negative breast cancer: Analysis of four prospective studies
Peripheral blood lymphocytes predict clinical outcomes in hormone receptor-positive HER2-negative advanced breast cancer patients treated with CDK4/6 inhibitors
Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer
HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment
Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival
Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer
Survival after neoadjuvant therapy with trastuzumab–lapatinib and chemotherapy in patients with HER2-positive early breast cancer: a meta-analysis of randomized trials
A comprehensive profiling of the immune microenvironment of breast cancer brain metastases
HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1
Oligometastatic breast cancer: Dissecting the clinical and biological uniqueness of this emerging entity. Can we pursue curability?